Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application
Sarcomas are a group of heterogeneous malignancies of mesenchymal origin. Patient outcomes remain especially grim for those with recurrent or metastatic disease, and current therapeutic strategies have not significantly improved outcomes over the past few decades. This has led to a number of studies...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2020-06, Vol.479, p.54-60 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 60 |
|---|---|
| container_issue | |
| container_start_page | 54 |
| container_title | Cancer letters |
| container_volume | 479 |
| creator | Wei, Ran Dean, Dylan C. Thanindratarn, Pichaya Hornicek, Francis J. Guo, Wei Duan, Zhenfeng |
| description | Sarcomas are a group of heterogeneous malignancies of mesenchymal origin. Patient outcomes remain especially grim for those with recurrent or metastatic disease, and current therapeutic strategies have not significantly improved outcomes over the past few decades. This has led to a number of studies assessing novel therapies. Cancer testis antigens (CTAs) are tumor-associated antigens with physiologic expression in the testis and various malignancies, including sarcomas. Genes encoding CTAs include MAGE, NY-ESO-1, PRAME, TRAG-3/CSAGE, and SSX. The importance and function of CTAs in tumorigenesis have gained recognition in recent years. They are also proving as robust diagnostic and prognostic biomarkers. Therapeutically, antigens derived from CTAs are highly recognizable by T lymphocytes and therefore capable of generating a potent antitumor immune response. CTAs are, therefore, promising targets for novel immunotherapies. Here we review the emerging works on expression, function, and immunotherapeutic application of CTAs in sarcoma therapy.
•Cancer testis antigens (CTAs) are commonly expressed in sarcomas.•Expression of CTAs is proving as robust diagnostic and prognostic biomarkers.•CTAs are promising targets for novel sarcoma immunotherapies. |
| doi_str_mv | 10.1016/j.canlet.2019.10.024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2307729943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030438351930521X</els_id><sourcerecordid>2425683755</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-22251148c39112f3e5c1ac7932ce3de7cf156724f086de0f613ec4ff733bd8383</originalsourceid><addsrcrecordid>eNp9kEtv1DAQgC1URLeFf4BQpF44kMXPOOmhElptC9JKXODAyfJOxtSrxAm2g-Df49W2PfTAaUajb14fIW8ZXTPKmo-HNdgwYF5zyrpSWlMuX5AVazWvddfSM7KigspatEKdk4uUDpRSJbV6Rc4Fa4RUvFmRHxsbAGOVMWWfKhuy_4khVT5UyUaYRntdbf_MEVPyU_hQuSVALlkh-8qP4xKmfI_RzrhkD5Wd58GDPRKvyUtnh4RvHuIl-X67_bb5XO--3n3ZfNrVIFWTa865Yky2IDrGuBOogFnQneCAokcNjqlGc-lo2_RIXcMEgnROC7Hv2_LcJXl_mjvH6ddS3jCjT4DDYANOSzJcUK1510lR0Ktn6GFaYijXGS65alqhlSqUPFEQp5QiOjNHP9r41zBqjurNwZzUm6P6Y7WoL23vHoYv-xH7p6ZH1wW4OQFYbPz2GE0Cj8V-7yNCNv3k_7_hH7JIlpc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425683755</pqid></control><display><type>article</type><title>Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wei, Ran ; Dean, Dylan C. ; Thanindratarn, Pichaya ; Hornicek, Francis J. ; Guo, Wei ; Duan, Zhenfeng</creator><creatorcontrib>Wei, Ran ; Dean, Dylan C. ; Thanindratarn, Pichaya ; Hornicek, Francis J. ; Guo, Wei ; Duan, Zhenfeng</creatorcontrib><description>Sarcomas are a group of heterogeneous malignancies of mesenchymal origin. Patient outcomes remain especially grim for those with recurrent or metastatic disease, and current therapeutic strategies have not significantly improved outcomes over the past few decades. This has led to a number of studies assessing novel therapies. Cancer testis antigens (CTAs) are tumor-associated antigens with physiologic expression in the testis and various malignancies, including sarcomas. Genes encoding CTAs include MAGE, NY-ESO-1, PRAME, TRAG-3/CSAGE, and SSX. The importance and function of CTAs in tumorigenesis have gained recognition in recent years. They are also proving as robust diagnostic and prognostic biomarkers. Therapeutically, antigens derived from CTAs are highly recognizable by T lymphocytes and therefore capable of generating a potent antitumor immune response. CTAs are, therefore, promising targets for novel immunotherapies. Here we review the emerging works on expression, function, and immunotherapeutic application of CTAs in sarcoma therapy.
•Cancer testis antigens (CTAs) are commonly expressed in sarcomas.•Expression of CTAs is proving as robust diagnostic and prognostic biomarkers.•CTAs are promising targets for novel sarcoma immunotherapies.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2019.10.024</identifier><identifier>PMID: 31634526</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Antigen (tumor-associated) ; Antigens ; Antigens, Neoplasm - metabolism ; Antitumor activity ; Biomarkers ; Biomarkers, Tumor - metabolism ; Bone cancer ; Cancer testis antigen ; Cancer therapies ; Cell adhesion & migration ; Cell growth ; Drug resistance ; Esophagus ; Ewings sarcoma ; Expression ; Function ; Gene Expression Regulation, Neoplastic ; Genes ; Humans ; Immune response ; Immunotherapy ; Liposarcoma ; Lymphocytes T ; Medical prognosis ; Medical research ; Melanoma ; Mesenchyme ; Metastases ; Metastasis ; Ovaries ; Patients ; Protein expression ; Proteins ; Sarcoma ; Sarcoma - drug therapy ; Sarcoma - metabolism ; Stem cells ; T-Lymphocytes - immunology ; Testes ; Tumorigenesis ; Tumors</subject><ispartof>Cancer letters, 2020-06, Vol.479, p.54-60</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><rights>2019. Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-22251148c39112f3e5c1ac7932ce3de7cf156724f086de0f613ec4ff733bd8383</citedby><cites>FETCH-LOGICAL-c456t-22251148c39112f3e5c1ac7932ce3de7cf156724f086de0f613ec4ff733bd8383</cites><orcidid>0000-0003-2471-5767 ; 0000-0001-7276-3910 ; 0000-0001-6965-9354</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S030438351930521X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31634526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wei, Ran</creatorcontrib><creatorcontrib>Dean, Dylan C.</creatorcontrib><creatorcontrib>Thanindratarn, Pichaya</creatorcontrib><creatorcontrib>Hornicek, Francis J.</creatorcontrib><creatorcontrib>Guo, Wei</creatorcontrib><creatorcontrib>Duan, Zhenfeng</creatorcontrib><title>Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Sarcomas are a group of heterogeneous malignancies of mesenchymal origin. Patient outcomes remain especially grim for those with recurrent or metastatic disease, and current therapeutic strategies have not significantly improved outcomes over the past few decades. This has led to a number of studies assessing novel therapies. Cancer testis antigens (CTAs) are tumor-associated antigens with physiologic expression in the testis and various malignancies, including sarcomas. Genes encoding CTAs include MAGE, NY-ESO-1, PRAME, TRAG-3/CSAGE, and SSX. The importance and function of CTAs in tumorigenesis have gained recognition in recent years. They are also proving as robust diagnostic and prognostic biomarkers. Therapeutically, antigens derived from CTAs are highly recognizable by T lymphocytes and therefore capable of generating a potent antitumor immune response. CTAs are, therefore, promising targets for novel immunotherapies. Here we review the emerging works on expression, function, and immunotherapeutic application of CTAs in sarcoma therapy.
•Cancer testis antigens (CTAs) are commonly expressed in sarcomas.•Expression of CTAs is proving as robust diagnostic and prognostic biomarkers.•CTAs are promising targets for novel sarcoma immunotherapies.</description><subject>Antigen (tumor-associated)</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Antitumor activity</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Bone cancer</subject><subject>Cancer testis antigen</subject><subject>Cancer therapies</subject><subject>Cell adhesion & migration</subject><subject>Cell growth</subject><subject>Drug resistance</subject><subject>Esophagus</subject><subject>Ewings sarcoma</subject><subject>Expression</subject><subject>Function</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genes</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunotherapy</subject><subject>Liposarcoma</subject><subject>Lymphocytes T</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Melanoma</subject><subject>Mesenchyme</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Ovaries</subject><subject>Patients</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Sarcoma</subject><subject>Sarcoma - drug therapy</subject><subject>Sarcoma - metabolism</subject><subject>Stem cells</subject><subject>T-Lymphocytes - immunology</subject><subject>Testes</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtv1DAQgC1URLeFf4BQpF44kMXPOOmhElptC9JKXODAyfJOxtSrxAm2g-Df49W2PfTAaUajb14fIW8ZXTPKmo-HNdgwYF5zyrpSWlMuX5AVazWvddfSM7KigspatEKdk4uUDpRSJbV6Rc4Fa4RUvFmRHxsbAGOVMWWfKhuy_4khVT5UyUaYRntdbf_MEVPyU_hQuSVALlkh-8qP4xKmfI_RzrhkD5Wd58GDPRKvyUtnh4RvHuIl-X67_bb5XO--3n3ZfNrVIFWTa865Yky2IDrGuBOogFnQneCAokcNjqlGc-lo2_RIXcMEgnROC7Hv2_LcJXl_mjvH6ddS3jCjT4DDYANOSzJcUK1510lR0Ktn6GFaYijXGS65alqhlSqUPFEQp5QiOjNHP9r41zBqjurNwZzUm6P6Y7WoL23vHoYv-xH7p6ZH1wW4OQFYbPz2GE0Cj8V-7yNCNv3k_7_hH7JIlpc</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Wei, Ran</creator><creator>Dean, Dylan C.</creator><creator>Thanindratarn, Pichaya</creator><creator>Hornicek, Francis J.</creator><creator>Guo, Wei</creator><creator>Duan, Zhenfeng</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2471-5767</orcidid><orcidid>https://orcid.org/0000-0001-7276-3910</orcidid><orcidid>https://orcid.org/0000-0001-6965-9354</orcidid></search><sort><creationdate>20200601</creationdate><title>Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application</title><author>Wei, Ran ; Dean, Dylan C. ; Thanindratarn, Pichaya ; Hornicek, Francis J. ; Guo, Wei ; Duan, Zhenfeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-22251148c39112f3e5c1ac7932ce3de7cf156724f086de0f613ec4ff733bd8383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antigen (tumor-associated)</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Antitumor activity</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Bone cancer</topic><topic>Cancer testis antigen</topic><topic>Cancer therapies</topic><topic>Cell adhesion & migration</topic><topic>Cell growth</topic><topic>Drug resistance</topic><topic>Esophagus</topic><topic>Ewings sarcoma</topic><topic>Expression</topic><topic>Function</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genes</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunotherapy</topic><topic>Liposarcoma</topic><topic>Lymphocytes T</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Melanoma</topic><topic>Mesenchyme</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Ovaries</topic><topic>Patients</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Sarcoma</topic><topic>Sarcoma - drug therapy</topic><topic>Sarcoma - metabolism</topic><topic>Stem cells</topic><topic>T-Lymphocytes - immunology</topic><topic>Testes</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wei, Ran</creatorcontrib><creatorcontrib>Dean, Dylan C.</creatorcontrib><creatorcontrib>Thanindratarn, Pichaya</creatorcontrib><creatorcontrib>Hornicek, Francis J.</creatorcontrib><creatorcontrib>Guo, Wei</creatorcontrib><creatorcontrib>Duan, Zhenfeng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wei, Ran</au><au>Dean, Dylan C.</au><au>Thanindratarn, Pichaya</au><au>Hornicek, Francis J.</au><au>Guo, Wei</au><au>Duan, Zhenfeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>479</volume><spage>54</spage><epage>60</epage><pages>54-60</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Sarcomas are a group of heterogeneous malignancies of mesenchymal origin. Patient outcomes remain especially grim for those with recurrent or metastatic disease, and current therapeutic strategies have not significantly improved outcomes over the past few decades. This has led to a number of studies assessing novel therapies. Cancer testis antigens (CTAs) are tumor-associated antigens with physiologic expression in the testis and various malignancies, including sarcomas. Genes encoding CTAs include MAGE, NY-ESO-1, PRAME, TRAG-3/CSAGE, and SSX. The importance and function of CTAs in tumorigenesis have gained recognition in recent years. They are also proving as robust diagnostic and prognostic biomarkers. Therapeutically, antigens derived from CTAs are highly recognizable by T lymphocytes and therefore capable of generating a potent antitumor immune response. CTAs are, therefore, promising targets for novel immunotherapies. Here we review the emerging works on expression, function, and immunotherapeutic application of CTAs in sarcoma therapy.
•Cancer testis antigens (CTAs) are commonly expressed in sarcomas.•Expression of CTAs is proving as robust diagnostic and prognostic biomarkers.•CTAs are promising targets for novel sarcoma immunotherapies.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>31634526</pmid><doi>10.1016/j.canlet.2019.10.024</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2471-5767</orcidid><orcidid>https://orcid.org/0000-0001-7276-3910</orcidid><orcidid>https://orcid.org/0000-0001-6965-9354</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2020-06, Vol.479, p.54-60 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2307729943 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antigen (tumor-associated) Antigens Antigens, Neoplasm - metabolism Antitumor activity Biomarkers Biomarkers, Tumor - metabolism Bone cancer Cancer testis antigen Cancer therapies Cell adhesion & migration Cell growth Drug resistance Esophagus Ewings sarcoma Expression Function Gene Expression Regulation, Neoplastic Genes Humans Immune response Immunotherapy Liposarcoma Lymphocytes T Medical prognosis Medical research Melanoma Mesenchyme Metastases Metastasis Ovaries Patients Protein expression Proteins Sarcoma Sarcoma - drug therapy Sarcoma - metabolism Stem cells T-Lymphocytes - immunology Testes Tumorigenesis Tumors |
| title | Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T02%3A54%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20testis%20antigens%20in%20sarcoma:%20Expression,%20function%20and%20immunotherapeutic%20application&rft.jtitle=Cancer%20letters&rft.au=Wei,%20Ran&rft.date=2020-06-01&rft.volume=479&rft.spage=54&rft.epage=60&rft.pages=54-60&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2019.10.024&rft_dat=%3Cproquest_cross%3E2425683755%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425683755&rft_id=info:pmid/31634526&rft_els_id=S030438351930521X&rfr_iscdi=true |